What Is Melanotan?
Melanotan is a collective term for a family of synthetic peptide analogs of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide produced in the pituitary gland. α-MSH binds to melanocortin receptors throughout the body — most notably the melanocortin-1 receptor (MC1R) found on melanocytes, the pigment-producing cells in skin.
When α-MSH activates MC1R, melanocytes produce more melanin — the dark pigment responsible for skin, hair, and eye color. Melanin comes in two primary forms:
- Eumelanin — dark brown/black pigment responsible for dark skin, hair, and tanning response
- Pheomelanin — red/yellow pigment responsible for freckles, red hair, and lighter skin tones
The ratio and distribution of these pigments determines an individual's skin tone and UV response. The goal of Melanotan peptides is to shift this balance toward eumelanin production — increasing the skin's natural darkening response to UV exposure.
Two variants of Melanotan have been the subject of the most research and user community interest:
- Melanotan I (MT-I) — also known as afamelanotide in its clinical form; a 16-amino-acid linear peptide
- Melanotan II (MT-II) — a cyclic 6-amino-acid peptide with additional pharmacological activity beyond MC1R
Both were originally developed by researchers at the University of Arizona in the 1980s as potential agents for preventing skin cancer by stimulating natural UV-protective pigmentation. The research has since expanded in multiple directions, with regulatory outcomes that differ significantly between the two variants.
Melanotan I (afamelanotide): Linear 16-amino-acid α-MSH analog; MC1R-selective; primary use: skin pigmentation. | Melanotan II: Cyclic 6-amino-acid peptide; MC1R + MC3/MC4 activity; broader effects including sexual arousal and appetite. | FDA-approved: Only afamelanotide (Scenesse) for EPP | Human clinical trials: Limited, mostly for afamelanotide
Melanotan I vs Melanotan II: What's the Difference?
The two variants share a common origin and target receptor, but their pharmacology, clinical development paths, and risk profiles are meaningfully different.
| Property | Melanotan I (Afamelanotide) | Melanotan II |
|---|---|---|
| Structure | Linear 16 amino acids | Cyclic 6 amino acids |
| Primary Target | MC1R (melanocortin-1 receptor) | MC1R + MC3R + MC4R |
| Melanin Effect | Direct and selective | Present, but less selective |
| Other Effects | Minimal beyond pigmentation | Appetite suppression, arousal, erectile function |
| FDA Status | Approved (Scenesse, for EPP) | Not approved for any indication |
| Clinical Development | Multiple Phase II–III trials | Minimal formal clinical development |
| Common Use | Skin pigmentation, EPP treatment | Tanning, aphrodisiac research |
| Legal Availability | Prescription only (Scenesse implant) | Gray market / research chemical |
Melanotan I / Afamelanotide
Melanotan I is the more precisely targeted of the two. Its 16-amino-acid structure is closer to native α-MSH and shows high selectivity for the MC1R receptor. The FDA-approved form is called Scenesse (afamelanotide), delivered as a subcutaneous implant that releases the peptide over approximately two months.
Scenesse is specifically approved for erythropoietic protoporphyria (EPP) — a rare genetic disorder in which patients experience severe, painful photosensitivity reactions to visible light. This is a narrow, clinically defined indication with genuine unmet need — these patients have had essentially no effective treatment options.
The mechanism in EPP is the same as in healthy skin: increased melanin provides photoprotection. For EPP patients, even modest melanin increases can mean the difference between being able to go outside during daylight and being essentially housebound.
Melanotan II
Melanotan II's cyclic structure is more stable than Melanotan I and it binds not only to MC1R but also to MC3R and MC4R — melanocortin receptors found in the brain involved in appetite regulation, sexual arousal, and autonomic function.
The additional receptor activity means Melanotan II produces effects beyond skin darkening:
- Sexual arousal — MC4R activation in the CNS is associated with erectile function and libido. Melanotan II was investigated as a treatment for erectile dysfunction before the research was shelved.
- Appetite suppression — MC3R/MC4R activity in the hypothalamus affects feeding behavior. Melanotan II shows consistent appetite-suppressing effects in animal models.
- Darker tan with less UV exposure — because it also activates MC1R, the tanning effect is present, but typically requires lower UV doses to achieve equivalent pigmentation compared to untreated skin.
Melanotan II has no FDA-approved indication and no formal clinical development program. Its use is entirely off-label and occurs in a regulatory gray area.
How Melanotan Works: The Biology of Melanin
Understanding how Melanotan produces its effects requires a short detour through skin biology.
The Melanocortin System
The melanocortin system is a family of peptides and receptors (MC1R through MC5R) involved in a wide range of functions: skin pigmentation, inflammation, energy homeostasis, sexual function, and blood pressure regulation. α-MSH is the body's primary endogenous agonist for these receptors.
When α-MSH binds to MC1R on a melanocyte, it triggers a signaling cascade that activates tyrosinase — the rate-limiting enzyme in melanin synthesis. Tyrosinase converts the amino acid tyrosine into DOPA, then into dopaquinone, which is the entry point into the eumelanin and pheomelanin synthesis pathways. More active tyrosinase means more melanin production.
Melanotan peptides are designed to be more stable than native α-MSH (which is rapidly degraded in the bloodstream) and to have higher binding affinity for MC1R. The result is a more sustained and potent activation of the melanogenesis pathway.
The UV Protection Hypothesis
The original motivation for developing Melanotan was the observation that people with darker skin (more eumelanin) have significantly lower rates of melanoma and non-melanoma skin cancers than people with fair skin. The theory: if you can increase melanin levels without requiring dangerous levels of UV exposure, you could reduce skin cancer incidence.
This hypothesis is biologically coherent. Eumelanin absorbs and scatters UV radiation, providing genuine photoprotection. Fair-skinned individuals with poor tanning responses carry a substantially higher lifetime risk of UV-induced skin damage and skin cancer.
The complication is that the relationship between artificial melanin stimulation and cancer outcomes is not straightforwardly positive — see the Safety section below.
Melanotan peptides activate melanocortin-1 receptors (MC1R) on skin melanocytes, which upregulates tyrosinase activity and increases eumelanin synthesis. Eumelanin is then packaged into melanosomes and distributed throughout the epidermis, darkening the skin and providing varying degrees of UV photoprotection.
The Research: What's Actually Been Studied
Melanotan research falls into two distinct bodies of work: the clinical research on afamelanotide (Melanotan I) for EPP and related conditions, and the largely preclinical work on Melanotan II and broader applications.
Afamelanotide (Melanotan I) Clinical Research
This is the better-developed evidence base. Afamelanotide has undergone multiple Phase II and Phase III clinical trials, primarily for:
- Erythropoietic protoporphyria (EPP): The FDA approval basis. Two randomized, double-blind Phase III trials (CpG010 and CpG011) demonstrated statistically significant increases in pain-free sun exposure compared to placebo. The effect size was clinically meaningful for a condition with essentially no prior treatment options.
- Polymorphic light eruption (PMLE): A condition of abnormal sun sensitivity. A 2020 randomized trial showed afamelanotide reduced disease severity and improved quality of life scores.
- Photoprotection in general populations: Small studies in healthy volunteers have shown that afamelanotide increases melanin density and reduces UV-induced DNA damage (measured via thymine dimer formation) in skin biopsies. This is mechanistically consistent but does not yet constitute clinical evidence that skin cancer rates are reduced.
- Vitiligo: Some pilot studies have investigated afamelanotide as a repigmentation agent for vitiligo, with preliminary results showing modest benefit in some patients — consistent with the melanocyte-stimulating mechanism.
Melanotan II Research
Melanotan II has a more scattered research record. Much of the human data comes from small clinical pharmacology studies in the 1990s–2000s focused on its effects on erectile function and sexual arousal. The tanning effect was consistently observed, but formal clinical development for cosmetic use was not pursued.
Preclinical research (primarily rodent models) has investigated:
- Appetite and energy expenditure effects via MC4R
- Neuroprotective effects in models of Parkinson's disease
- Anti-inflammatory effects in models of metabolic disease
- Cardiovascular effects via melanocortin receptors in the periphery
None of these indications have advanced to human clinical trials in a meaningful way.
The clinical research on Melanotan-family peptides is largely limited to afamelanotide (Melanotan I) for specific photosensitivity disorders. The tanning use that dominates online communities is not what these compounds were developed for, and the evidence base for cosmetic tanning use specifically is substantially weaker than for the approved clinical indications.
Common Uses and User Reports
Despite the regulatory complexity, Melanotan peptides have developed substantial off-label user communities. Understanding these uses requires separating the documented applications from the anecdotal ones.
Cosmetic Tanning
This is by far the most common use in online communities — people using Melanotan I or II to achieve a tan without sun exposure, or to enhance tanning response with reduced UV exposure. The appeal is straightforward: skin darkens, and the appearance of tan persists for weeks to months without daily sunbed sessions.
The informal user report dataset is substantial. Common observations from user communities:
- Visible darkening typically begins within 3–7 days of regular dosing
- The tan is less UV-dependent than natural tanning — users report darkening even with minimal sun exposure
- The effect is dose-dependent and reversible: melanin levels decline over weeks to months after stopping
- Melanotan II users report the additional effects on libido and appetite alongside the tanning effect
These reports are consistent with the known pharmacology, but they are not clinical data. As with all anecdotal datasets, selection bias and placebo effects are significant confounds.
Skin Cancer Prevention (Theoretical)
Some users take Melanotan specifically for the photoprotection hypothesis — the idea that increased melanin reduces UV-induced DNA damage and therefore skin cancer risk. This is the original rationale for developing these peptides and the logic is biologically sound. However, it remains unproven as a clinical intervention for cancer prevention in healthy individuals.
EPP and Photosensitivity Disorders
This is the only indication with FDA approval. Scenesse (afamelanotide implant) is prescribed by specialists for patients with confirmed EPP. This is genuine, medically supervised clinical use — not the same as cosmetic self-administration.
Questions About Peptides?
WellSourced covers peptide mechanisms, dosing considerations, and research evidence. Ask the community or explore our other guides.
Read More Articles Ask a QuestionBodybuilding and Aesthetic Community
Within bodybuilding and fitness circles, Melanotan II in particular has been used to achieve and maintain a year-round tan as part of a "aesthetic" presentation — particularly in the lead-up to competitions where skin tone affects the appearance of muscle definition. Some users also report appetite-suppressing effects as a secondary benefit during cutting phases.
Safety, Side Effects, and Risks
Safety assessment for Melanotan peptides requires distinguishing between the documented safety profile of afamelanotide in its approved clinical use, and the informal safety record of off-label peptide administration.
Afamelanotide (FDA-Approved Use)
In clinical trials and post-approval monitoring for EPP, afamelanotide's safety profile was characterized in controlled settings. Common adverse effects observed:
- Injection site reactions — the most frequently reported adverse effect; typically mild erythema or discomfort at the implant site
- Skin hyperpigmentation — the intended effect, but can be uneven or excessive in some patients
- Nausea — reported in a minority of patients in clinical trials
- Yawning and stretching — a curious and consistent side effect in EPP trials; appears related to melanocortin signaling in the CNS
- Headache — mild, transient
Off-Label Peptide Use: What the Informal Record Shows
The user community data (forums, social media, retrospective reports) is the primary source of information on off-label Melanotan II use. Commonly reported effects:
- Increased libido and sexual arousal — particularly with Melanotan II; dose-dependent, sometimes pronounced
- Nausea — common in the first days of use, usually transient
- Flushing — vasodilation-related facial redness, typically transient
- Appetite suppression — more common with Melanotan II
- Darkening of existing moles and freckles — expected given the mechanism, but requires dermatological monitoring
- Facial darkening (melasma-like effects) — uneven hyperpigmentation in some users, particularly on the face
Melanotan peptides stimulate melanocytes — the cells that give rise to melanoma. There is documented evidence that some melanotan-related compounds can promote melanoma growth in animal models and that melanocyte proliferation can be induced. For individuals with existing nevi (moles), a personal or family history of melanoma, or other skin cancer risk factors, this is not a theoretical concern — it is a documented pharmacological effect that warrants serious discussion with a dermatologist before use.
Other Risks Worth Taking Seriously
- Quality and purity: Off-label peptides are almost entirely obtained through research chemical suppliers or compounding pharmacies. Purity, sterility, and accurate labeling vary significantly. Unlike FDA-approved Scenesse (which is a regulated medical product), unverified peptide products carry contamination and mislabeling risk independent of the compound itself.
- No medical supervision: Most off-label use occurs without involvement of a qualified healthcare provider — no baseline skin assessment, no monitoring for suspicious lesions, no guidance on dosing.
- The tan is not a substitute for sunscreen: Melanotan-induced tanning increases melanin but does not provide complete UV protection. Users who mistakenly believe they are protected from UV damage may increase sun exposure and sustain more net harm than no-tan users.
- Unknown long-term effects: There is no long-term human safety data for regular Melanotan II use. The biological plausibility of both benefit and harm in long-term use scenarios is significant.
Legal Status: The Regulatory Landscape
The legal status of Melanotan peptides differs significantly between the two variants and is highly jurisdiction-dependent.
United States
In the US, Melanotan I (afamelanotide) is the only FDA-approved compound in this class — under the brand name Scenesse, approved specifically for erythropoietic protoporphyria. It is available only by prescription and dispensed as a regulated implant through specialty pharmacies.
Melanotan II is not an FDA-approved drug for any indication. The FDA has taken enforcement action against companies marketing Melanotan II as a tanning product, sending warning letters for marketing an unapproved new drug. Possession and personal use by individuals has not been a common enforcement target, but the regulatory status is unambiguously gray.
The general availability of "research peptides" through online suppliers exists in a legal space that is contested but not clearly illegal at the individual possession level. The sale for human use is generally considered a violation of FDA regulations.
Europe and Other Jurisdictions
Scenesse is approved in the EU (via the European Medicines Agency) for EPP. Outside of the approved indication, the regulatory status of Melanotan peptides across EU member states is variable.
In Australia, afamelanotide went through a specific approval process via the TGA. Melanotan II availability has been subject to regulatory scrutiny similar to the US.
The fact that a compound is widely discussed online and relatively easy to obtain through certain supplier channels does not indicate regulatory approval or legal availability for human use. The regulatory landscape changes — what is nominally tolerated today may be subject to enforcement action tomorrow. Anyone considering off-label use should be aware of the current legal status in their specific jurisdiction.
Bottom Line
Melanotan peptides occupy an interesting and somewhat contradictory position in the research peptide landscape: one variant (afamelanotide/Melanotan I) has FDA approval for a legitimate, narrow clinical indication, while the same compound family is widely used off-label for cosmetic purposes without regulatory authorization or adequate safety data.
What We Know
- Melanotan I (afamelanotide) has a meaningful, FDA-confirmed benefit for EPP patients — this is the clearest evidence of efficacy in the compound family
- Melanotan peptides reliably increase melanin production in humans, with measurable effects on skin pigmentation
- The mechanism — MC1R activation and tyrosinase upregulation — is well-characterized in vitro and in vivo
- Melanotan II has additional CNS effects (arousal, appetite) via MC3R/MC4R, which are documented but not clinically developed
- The photoprotection hypothesis is biologically coherent but not yet confirmed in clinical cancer-prevention trials
What Remains Unproven or Unresolved
- Efficacy of Melanotan I or II for cosmetic tanning use — documented in terms of melanin increase, but without controlled trials specifically for this indication
- Long-term safety of regular use in healthy individuals — essentially no data
- The melanoma concern is real and biologically grounded — the mechanism that increases melanin also stimulates melanocyte proliferation. For individuals with risk factors for skin cancer, this is not dismissible as theoretical
- Quality and safety of off-label peptide products obtained through non-regulated supply chains
- Whether Melanotan use reduces, increases, or has no effect on net skin cancer risk — the UV protection benefit could be partially or fully offset by melanocyte stimulation risks
Melanotan peptides are not fringe compounds — one variant (afamelanotide) is an FDA-approved medicine for patients with a genuinely debilitating condition. The cosmetic tanning use is understandable but carries unresolved safety questions that the approved use does not address. If you're considering Melanotan, especially for cosmetic purposes, the minimum standard should be: dermatologist evaluation before starting, medical supervision during use, and honest assessment of whether the aesthetic benefit justifies the known unknowns. The most defensible use case for these compounds remains their approved clinical application.